Literature DB >> 15016963

High frequency of mutations of the PIK3CA gene in human cancers.

Yardena Samuels1, Zhenghe Wang, Alberto Bardelli, Natalie Silliman, Janine Ptak, Steve Szabo, Hai Yan, Adi Gazdar, Steven M Powell, Gregory J Riggins, James K V Willson, Sanford Markowitz, Kenneth W Kinzler, Bert Vogelstein, Victor E Velculescu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15016963     DOI： 10.1126/science.1096502

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  1351 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Authors:  Brian G Blair; Xinyan Wu; Muhammad Saddiq Zahari; Morassa Mohseni; Justin Cidado; Hong Yuen Wong; Julia A Beaver; Rory L Cochran; Daniel J Zabransky; Sarah Croessmann; David Chu; Patricia Valda Toro; Karen Cravero; Akhilesh Pandey; Ben Ho Park
Journal:  Proteomics       Date:  2014-12-28       Impact factor: 3.984

3.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 4.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

5.  Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.

Authors:  Braden D Siempelkamp; Manoj K Rathinaswamy; Meredith L Jenkins; John E Burke
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

6.  Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

Authors:  Sida Shen; Xiangyu He; Zheng Yang; Liang Zhang; Yingtao Liu; Zhiyuan Zhang; Weiwei Wang; Wei Liu; Yufeng Li; Dong Huang; Kai Sun; Xiaojing Ni; Xu Yang; Xinxin Chu; Yumin Cui; Qiang Lv; Jiong Lan; Fusheng Zhou
Journal:  ACS Med Chem Lett       Date:  2018-06-25       Impact factor: 4.345

7.  Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Scott J Cotler; Nissim Hay; Hui Xie; Mei Ling Chen; Pei Zhang Xu; Thomas J Layden; Grace Guzman
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

Review 8.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

9.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

10.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.